COVID-19, and its disproportionate effect on minority populations highlighted the need for increased diversity in clinical trials in order to adequately treat every patient population. The biopharma industry has resisted diversification in the past because its...
Once a seemingly far-fetched endeavor, decentralized clinical trials are gaining favor in the wake of COVID-19. It has become clear that the time for entirely in-person clinical trials has passed, paving the way for a new, technologically integrated approach. This...
At the end of this uniquely challenging year, MVG Consulting would like to take a moment to thank those who have had an indelible impact throughout this difficult time. To the frontline workers, who have worked tirelessly, adapting to every changing circumstance this...